

Mauricio A Cuello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8527501/publications.pdf>

Version: 2024-02-01

62
papers

2,832
citations

236925

25
h-index

175258

52
g-index

71
all docs

71
docs citations

71
times ranked

4062
citing authors

#	ARTICLE	IF	CITATIONS
1	Infantile/Capillary Hemangioma of the Uterine Corpus: A Rare Cause of Abnormal Genital Bleeding. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2022, 35, 597-600.	0.7	2
2	D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy. <i>Cancers</i> , 2021, 13, 3622.	3.7	5
3	FIGO staging for carcinoma of the vulva: 2021 revision. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 43-47.	2.3	42
4	Cancer of the vulva: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 7-18.	2.3	58
5	Obesity and gynecological cancers: A toxic relationship. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 123-134.	2.3	13
6	Cancer of the vagina: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 19-27.	2.3	38
7	Multi-Objective Optimization for Personalized Prediction of Venous Thromboembolism in Ovarian Cancer Patients. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 1500-1508.	6.3	14
8	Clinical research in Chile: do not block the way of inquiry. <i>Lancet, The</i> , 2020, 396, 668.	13.7	0
9	Revised FIGO staging for carcinoma of the cervix uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 129-135.	2.3	612
10	5â€¦The good prognosis of immunoreactive subtype of high-grade serous ovarian cancer (HGSOC) is negatively impacted when obesity and lipid metabolism-related genes are highly expressed. , 2019, , .		1
11	Postmenopausal androgen-secreting ovarian tumors: challenging differential diagnosis in two cases. <i>Climacteric</i> , 2019, 22, 324-328.	2.4	3
12	EP919â€¦Obesity and inflammation combined are risk factor for early recurrence in High Grade Serous Ovarian Cancer. , 2019, , .		1
13	The impact on highâ€¦grade serous ovarian cancer of obesity and lipid metabolismâ€¦related gene expression patterns: the underestimated driving force affecting prognosis. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 1805-1815.	3.6	20
14	The value of endocervical curettage during loop electrosurgical excision procedures in predicting persistent/recurrent preinvasive cervical disease. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 141, 337-343.	2.3	6
15	Cancer of the vulva. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 4-13.	2.3	112
16	Cancer of the vagina. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 14-21.	2.3	87
17	Simvastatin interferes with cancer â€¦stem-cellâ€™ plasticity reducing metastasis in ovarian cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 821-836.	3.1	29
18	Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 10-17.	1.4	88

#	ARTICLE	IF	CITATIONS
19	P3.03-035 Prognostic Role of hENT1 and RRM1 in Patients with Advanced Pleural Mesothelioma Treated with Second Line Gemcitabine Based Regimens. Journal of Thoracic Oncology, 2017, 12, S1366-S1367.	1.1	0
20	Structural and functional identification of vasculogenic mimicry in vitro. Scientific Reports, 2017, 7, 6985.	3.3	42
21	El método CONO-UC: un protocolo integrado de toma de decisión y manejo de lesiones pre-invasoras del cuello uterino útil para especialistas jóvenes.. Revista Chilena De Obstetricia Y Ginecología, 2017, 82, 539-553.	0.1	1
22	Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression. Oncotarget, 2017, 8, 20865-20880.	1.8	25
23	Abstract 789: Establishment of an in vitro model for the study of vasculogenic mimicry in ovarian and gastrointestinal cancer cells. , 2017, , .		0
24	Abstract 5516: Regulation of TFPI-2 in the progression of ovarian cancer. , 2017, , .		0
25	Down-regulation of TFPI-2 in the progression of ovarian cancer. European Journal of Cancer, 2016, 61, S60.	2.8	0
26	Abstract B61: Leptin induces a pro-inflammatory macrophage-cancer cell reinforcement loop that favors high-grade serous ovarian cancer progression among overweight/obese women.. , 2016, , .		0
27	Impact of obesity on survival and recurrence of high grade serous carcinoma of the ovary.. Journal of Clinical Oncology, 2016, 34, e17081-e17081.	1.6	0
28	Total laparoscopic hysterectomy with previous cesarean section using a standardized technique: experience of Pontificia Universidad Catolica de Chile. Gynecological Surgery, 2015, 12, 149-155.	0.9	4
29	Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer, 2015, 15, 290.	2.6	85
30	Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor. Endocrine, 2015, 48, 309-320.	2.3	10
31	Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget, 2015, 6, 21100-21119.	1.8	88
32	Abstract 4314: Prediction of chemotherapy response and metabolism for the tailoring of ovarian cancer treatment. , 2015, , .		0
33	Abstract 2395: Leptin induces an IL-6 mediated interaction between macrophages and ovarian cancer cells that prompted invasiveness and migration. , 2015, , .		0
34	Independent Anti-Angiogenic Capacities of Coagulation Factors X and Xa. Journal of Cellular Physiology, 2014, 229, 1673-1680.	4.1	14
35	Labhardt's colpoperineocleisis: subjective results of an alternative treatment for genital prolapse in patients who are not sexually active—2-year follow-up. International Urogynecology Journal, 2014, 25, 417-424.	1.4	5
36	Abstract 1117: Platelet interaction induces Tissue Factor and a pro-metastatic phenotype in ovarian cancer cells. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
37	Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells. <i>Biomaterials</i> , 2013, 34, 4098-4108.	11.4	87
38	Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells. <i>Reproductive Sciences</i> , 2013, 20, 1433-1446.	2.5	52
39	Mechanical Stretch Increases Brain Natriuretic Peptide Production and Secretion in the Human Fetal Membranes. <i>Reproductive Sciences</i> , 2013, 20, 597-604.	2.5	3
40	Breaking through an epigenetic wall. <i>Epigenetics</i> , 2013, 8, 164-176.	2.7	20
41	Isoform Alpha of PKC May Contribute to the Maintenance of Pregnancy Myometrial Quiescence in Humans. <i>Reproductive Sciences</i> , 2013, 20, 69-77.	2.5	8
42	Abstract 3730: 2-Methoxyestradiol induces differentiation of epithelial ovarian cancer-initiating cells sensitizing them to chemotherapy.. , 2013, , .		0
43	Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors. <i>Journal of Biological Chemistry</i> , 2012, 287, 29873-29886.	3.4	38
44	Progesterone promotes focal adhesion formation and migration in breast cancer cells through induction of protease-activated receptor-1. <i>Journal of Endocrinology</i> , 2012, 214, 165-175.	2.6	25
45	Progesterone utilizes distinct membrane pools of tissue factor to increase coagulation and invasion and these effects are inhibited by TFPI. <i>Journal of Cellular Physiology</i> , 2011, 226, 3278-3285.	4.1	14
46	2-Methoxyestradiol Inhibits Progesterone-Dependent Tissue Factor Expression and Activity in Breast Cancer Cells. <i>Hormones and Cancer</i> , 2010, 1, 117-126.	4.9	10
47	Brain Natriuretic Peptide (BNP) Produced by the Human Chorioamnion May Mediate Pregnancy Myometrial Quiescence. <i>Reproductive Sciences</i> , 2009, 16, 32-42.	2.5	15
48	Lipophilic but not hydrophilic statins selectively induce cell death in gynecological cancers expressing high levels of HMGCoA reductase.. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 14, 1180-93.	3.6	110
49	Characterization and phenotypic variation with passage number of cultured human endometrial adenocarcinoma cells. <i>Tissue and Cell</i> , 2008, 40, 95-102.	2.2	21
50	2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts. <i>Reproductive Sciences</i> , 2008, 15, 878-894.	2.5	25
51	The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium. <i>Endocrine-Related Cancer</i> , 2007, 14, 351-368.	3.1	19
52	TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 73-85.	4.9	34
53	Mechanisms of Paracrine Regulation by Fetal Membranes of Human Uterine Quiescence. <i>Journal of the Society for Gynecologic Investigation</i> , 2006, 13, 343-349.	1.7	13
54	Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. <i>Thrombosis and Haemostasis</i> , 2005, 94, 444-53.	3.4	24

#	ARTICLE	IF	CITATIONS
55	N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. <i>Cell Death and Differentiation</i> , 2004, 11, 527-541.	11.2	38
56	Apoptosis and the treatment of breast cancer. <i>Breast Disease</i> , 2002, 15, 71-82.	0.8	5
57	Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer Cells. <i>Gynecologic Oncology</i> , 2001, 81, 380-390.	1.4	153
58	Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex. <i>Journal of Biological Chemistry</i> , 2001, 276, 27677-27684.	3.4	131
59	Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. <i>Cancer Research</i> , 2001, 61, 4892-900.	0.9	271
60	Inhibition of NF- κ B Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines. <i>Breast Cancer Research and Treatment</i> , 2000, 64, 211-219.	2.5	100
61	cbl-3: a new mammalian cbl family protein. <i>Oncogene</i> , 1999, 18, 3365-3375.	5.9	107
62	Analysis of mRNA Quality in Freshly Prepared and Archival Papanicolaou Samples. <i>Acta Cytologica</i> , 1999, 43, 831-836.	1.3	19